Attachment 2 - Page 5 
9306-EXP 
y306-050 
9306-051 
9306-052 
9309-053* 
9309-054 
9309-055 
5309-056 
9309-057 
9309-058 
93L2-059 
93L2-060 
9312-061 
9312-062 
93124>63 
(T) Sobol Robert and Roystoo, Ivor, San Diego Regional Cancer Center, San Diego, California; CONFIDENTIAL. 
NTH Approval; 12-28-92 
Major Amendment (Expedited Review)/N1H Approval; 5-11-93 
CLOSED: 10-20-93 (Pabenl death) 
(T) Raffel, Corey, Quldieos Hospital Los Angeles, Los Angeles, California, and Culver, Kenneth, Iowa Methodist Medical Center, Dcs 
Moines, Iowa; Gene Therapy for the Treaaneni of Recurrent Pediatric Malignant Astrocytomas with In Vivo Tumor Transduction with tlu 
Herpes Simples Thymidine Rinase Gene. 
RAC Approval: 6-8-93/NIH Approval: 9-3-93 
(T) Hesdorffer, Charles and Antman, Karen, Columbia University College of Physicians and Surgeons, New York, New York; Human 
MDR Gene Transfer in Patients with Advanced Cancer. 
RAC Approval 6-8-93/NIH Approval: 9-3-93 
(T) llan, Joseph, Case Western Reserve University School of Medicine and University Hospitals of Qeveland, Qcvcland, Ohio; Gene 
Therapy for Human Brain Tumors Using Episome-Based Antisense cDNA Transcription of Insulin-Like Growth Factor I. 
RAC Approval: 6-8-93/NlH Approval; 12-2-93 
fT) Cassileth, Peter, Podack, Eckhard R_; Sridhar, Kasi; University of Miami, and Savaraj, Nuamol; Miami Veterans Administration 
Hospital, Miami, Florida; Phase I Study of Transfected Cancer Cells Expressing the Interieuktn-2 Gene Product in Limited Stage Small 
Cell Lung Cancer. 
RAC Approval 9-9-93/NIH Approval 12-2-93 
Minor Modification: 3-23-94 
(T) O’Shaughnessy, Joyce; National Institutes of, Health, Bethesda, Maryland, Retroviral Mediaud Transfer of the Human Multi-Drug 
Resistance Gene (MDR-I) into Hematopoietic Stem Cells During Autologous Transplantation after Intensive Chemotherapy for Breast 
Cancer. 
RAC Approval 9-9-93/NIH Approval: 10-7-93 
(T) Kun, Larry E^’ Sanford, R A,; Brenner, Malcolm K.; and Heideroan, Richard L.; St. Jude Childrens Research Hospital, Memphis, 
Tennessee; and Oldfield, Edward H.; National Institutes of Health, Bethesda, Maryland; Gene Therapy for Recurrent Pediatric Brain 
Tumors. 
RAC Approval 9-9-93/NTH Approval; 10-7-93 
(T) Das Gupta, Tapas K. and Cohen, Edward P.; University of Illinois at Chicago; Chicago, Illinois, Immunization of Malignant 
Melanoma Patients with Interleukin 2-Secreting Melanoma Cells Expressing Defined Allogeneic Histocompatibility Antigens. 
RAC Approval 9-10-93/NIH Approval: 4-19-94 
(T) Wong-Staal, Flossie; Poeschla, Eric and Looney, David: Universitv of California, San Diego, California; A Phase I Oinical Trial to 
Evaluate the Safety and Effects in HTV-1 Infected Humans of Autologous Lymphocytes Transduced with a Ribozvme that Cleaves HIV-I 
RNA. 
RAC Approval: 9-10-93/NIH Approval: Pending 
(T) Economou, James S. and Glasby, John A,; University of California Medical Center, Los Angeles, California; Genetically Engineere. 
Autologous Tumor Vaccines Producing Interleukin-2 for the Treatment of Metastatic Melanoma. 
RAC Approval: 9-10-93/NlH Approval 12-2-93 
(T) Oldfield, Edward H. and Ram, Zvi; NIH, Bethesda, Maryland; Intrathecal Gene Therapy for the Treatment of Leptomeningeal 
Carcinomatosis. 
RAC Approval 12-2-93/NIH Approval 1-20- SM 
(T) Sobol, Robert E and Rovston. Ivor, San Diego Regional Cancer Center. San Diego. California; Injection of Colon Carcinoma 
Patients with Autolotous Irradiated Tumor Cells and Fibroblasts Genetically Modified to Secrete Interleukin-2. 
RAC Approval: 12-2-93/NlH Approval: Pending 
(T) Schuening. Friedrich: Fred Hutchinson Cancer Research Center, Seattle. Washington: Retrovirus-Mediated Transfe r of the cDNA for 
Human Glucocerebrosidase Into Peripheral Blood Repopulatine Cells of Patients with Gaucher's Disease. 
RAC Atmroval: 12-2-93/NlH Approval: Pending 
(T) Haubrich, Pichard; University of California at San Diego Treatment Center, San Diego, California; An Open Label. Phase I/D 
Clinical Trial to Evaluate the Sefety and Biological Activity of HIV-TTOO (HIV-1 HBenv/Retroviral Vector) in HTV-1 Irfected Subjects. 
RAC Approval 12-3-93/NIH Approval 4-19-94 
(T) Sznol, Mario; National Institutes of Health, Frederick, Maryland; A Phase I Trial of BT -Transfected LethaUy liTodiated Allogeneic 
Melanoma Cell Lines to Induce Cell Mediated Immunity Against Tumor-Associated Antigens Presented by HLA-A2 or HLA-AI in Patien 
with Stage TV Melanoma. 
BAC Approval 12-3-93/NDI Approval 4-19-94 
[378] 
Recombinant DNA Research, Volume 19 
